| Drug General Information |
| Drug ID |
D01ARG
|
| Former ID |
DIB000372
|
| Drug Name |
DB-900
|
| Indication |
Type 2 diabetes [ICD9: 250; ICD10:E11]
|
Investigative |
[1]
|
|---|
| Company |
DARA BioSciences
|
| Target and Pathway |
| Target(s) |
Peroxisome proliferator activated receptor alpha |
Target Info |
Agonist |
[1]
|
|---|
| Peroxisomeproliferator activated receptor delta |
Target Info |
Agonist |
[1]
|
| Peroxisome proliferator activated receptor gamma |
Target Info |
Agonist |
[1]
|
|
KEGG Pathway
|
PPAR signaling pathway
|
|
cAMP signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Glucagon signaling pathway
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Hepatitis Chsa03320:PPAR signaling pathway
|
|
Wnt signaling pathway
|
|
Pathways in cancer
|
|
Acute myeloid leukemiahsa03320:PPAR signaling pathway
|
|
AMPK signaling pathway
|
|
Osteoclast differentiation
|
|
Huntington's disease
|
|
Transcriptional misregulation in cancer
|
|
Thyroid cancer
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
PANTHER Pathway
|
Wnt signaling pathwayP06959:CCKR signaling map ST
|
|
Pathway Interaction Database
|
RXR and RAR heterodimerization with other nuclear receptorps1pathway:Presenilin action in Notch and Wnt signaling
|
|
RXR and RAR heterodimerization with other nuclear receptorwnt_noncanonical_pathway:Noncanonical Wnt signaling pathway
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Signaling events mediated by HDAC Class I
|
|
RXR and RAR heterodimerization with other nuclear receptor
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
RORA activates gene expression
|
|
BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
|
PPARA activates gene expression
|
|
YAP1- and WWTR1 (TAZ)-stimulated gene expression
|
|
Transcriptional activation of mitochondrial biogenesis
|
|
Activation of gene expression by SREBF (SREBP)
|
|
Transcriptional regulation of white adipocyte differentiation
|
|
Nuclear Receptor transcription pathway
|
|
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Circadian ClockR-HSA-200425:Import of palmitoyl-CoA into the mitochondrial matrix
|
|
Regulation of pyruvate dehydrogenase (PDH) complex
|
|
Nuclear Receptor transcription pathwayR-HSA-1989781:PPARA activates gene expression
|
|
WikiPathways
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Nuclear Receptors Meta-Pathway
|
|
Estrogen Receptor Pathway
|
|
PPAR Alpha Pathway
|
|
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
YAP1- and WWTR1 (TAZ)-stimulated gene expression
|
|
Activation of Gene Expression by SREBP (SREBF)
|
|
Adipogenesis
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
Circadian Clock
|
|
Nuclear ReceptorsWP399:Wnt Signaling Pathway and Pluripotency
|
|
NRF2 pathway
|
|
Vitamin D Receptor Pathway
|
|
Ectoderm Differentiation
|
|
Nuclear ReceptorsWP363:Wnt Signaling Pathway Netpath
|
|
Differentiation of white and brown adipocyte
|
|
SREBP signalling
|
|
Nuclear Receptors
|
| References |
| REF 1 | CN patent application no. 102459215, 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof. |
|---|
